Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-02

Study Completion Date

2023-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 1 clinical trial of SPH3348 tablets, a c-Met inhibitor, in patients with advanced solid tumors with c-Met abnormalities. A modified 3 + 3 design was adopted in patients with advanced solid tumors with c-Met abnormalities, with a total of 6 dose groups, in which accelerated dose escalation was adopted for the lowest dose group, and 3 + 3 dose escalation was adopted from the second dose group. The primary objective was to evaluate the safety and tolerability of SPH3348 tablets in patients with advanced solid tumors with c-Met abnormalities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

NCT06487455

Advanced Solid Tumor

RECRUITING PHASE1

A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

NCT06266923

Advanced Solid Tumor

COMPLETED EARLY_PHASE1

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

NCT05396391

Advanced Malignant Tumors

UNKNOWN PHASE1/PHASE2

A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

NCT03457532

Advanced Solid Tumor

COMPLETED PHASE1

A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors

NCT03844438

Solid Tumor

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SPH 3348 tablets

6 different dosage group of SPH 3348 will be assigned with 16mg, 40mg, 80mg, 160mg, 240mg and 320mg respectively.

Group Type EXPERIMENTAL

SPH 3348

Intervention Type DRUG

2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach

SPH 3348

Intervention Type DRUG

1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach

SPH 3348

Intervention Type DRUG

2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

SPH 3348

Intervention Type DRUG

4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

SPH 3348

Intervention Type DRUG

6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

SPH 3348

Intervention Type DRUG

8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SPH 3348

2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach

Intervention Type DRUG

SPH 3348

1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention Type DRUG

SPH 3348

2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention Type DRUG

SPH 3348

4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention Type DRUG

SPH 3348

6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention Type DRUG

SPH 3348

8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with advanced solid tumors with c-Met abnormalities who have failed standard of care or are not eligible for standard therapy currently
2. ECOG score of 0 or 1.
3. Patients must have measurable lesion that can be assessed by imaging per RECIST 1.1 criteria.
4. Expected survival \> 12 weeks.
5. Patients must have adequate organ function
6. Patients must give informed consent to the study and sign the informed consent form prior to the trial.

Exclusion Criteria

1. Received anti-tumor therapies, including but not limited to chemotherapy, biotherapy, radiotherapy, targeted therapy, etc., within 4 weeks prior to the first dose of study drug; received nitrosoureas or mitomycin C within 6 weeks prior to the start of study drug.
2. Received small molecule tyrosine kinase inhibitors within 2 weeks prior to the first dose.
3. Received strong CYP3A4 inducers or inhibitors or CYP3A4 substrates with narrow therapeutic windows within 2 weeks prior to the start of study drug.
4. Patients with active hepatitis B (hepatitis B surface antigen (HBsAg) positive) or hepatitis C (HCV).
5. Toxicities caused by prior treatments have not recovered to CTCAE Grade ≤ 1 or having ≥Grade 2 peripheral neuropathy, except for alopecia and other events judged as tolerable by the investigator.
6. Known allergy to any component of the reference drug.
7. Known drug or alcohol dependence.
8. Received surgical treatment including surgical and interventional procedures within 4 weeks prior to the start of study drug.
9. Patients with brain metastases.
10. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or evidence of any clinically active interstitial lung disease.
11. Acute bacterial, viral, or fungal infection requiring systemic therapy or unexplained fever (temperature \> 38.5 °C) during screening, prior to the first dose.
12. Neurological and psychiatric patients with obvious poor compliance.
13. Any of the following within 6 months prior to signing of informed consent form: uncontrolled congestive cardiac failure, severe or unstable angina pectoris, myocardial infarction, stroke, coronary/peripheral artery bypass surgery, pulmonary embolism.
14. Arrhythmia uncontrolled by medication or sustained QTcB prolongation.
15. Hypertension uncontrolled by medication
16. Participated in other drug clinical studies within 28 days prior to the first dose of study drug.
17. Women who are pregnant or in lactation period or women/men with childbearing plans.
18. Patients who cannot take oral medication, or have previous surgical history or serious gastrointestinal diseases such as dysphagia, active gastric ulcer, which may impair the absorption of the study drug in the investigator's opinion.
19. Other prior or current concomitant malignancies.
20. Patients who are ineligible to participate in this trial for any reason judged by the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No